Moleculin Biotech Partners with CIC biomaGUNE for Research

Moleculin Biotech ( (MBRX) ) has shared an update.

On December 8, 2025, Moleculin Biotech announced a research and material transfer agreement with CIC biomaGUNE to evaluate Annamycin for treating glioblastoma multiforme, a form of brain cancer. This collaboration aims to explore Annamycin’s potential in overcoming drug delivery challenges in central nervous system tumors, highlighting the company’s commitment to innovative cancer therapies.

The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.

Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.

To see Spark’s full report on MBRX stock, click here.

More about Moleculin Biotech

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, is designed to avoid multidrug resistance mechanisms and lacks the cardiotoxicity common with other anthracyclines. The company is also developing WP1066, an immune/transcription modulator, and other antimetabolites for cancer and viral treatments.

Average Trading Volume: 142,531

Technical Sentiment Signal: Sell

Current Market Cap: $14.96M

Find detailed analytics on MBRX stock on TipRanks’ Stock Analysis page.